Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety study of ETC 1002 in high-risk hyperlipidemia
NL-OMON45821Phase 3Active, not recruiting
- Sponsor
- Esperion Therapeutics
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hyperlipidemia and familial hypercholesterolemia (FH) comparing ETC 1002 plus background lipid-lowering therapy with Placebo plus background lipid-lowering therapy (2 arms). Primary endpoints: General safety, Treatment-emergent adverse events and 7 more. Started Jul 2016; status: active, not recruiting.
02
Drugs
bempedoic acid
03
Conditions
hyperlipidemiafamilial hypercholesterolemia (FH)
Beyond the preview
Go deeper on NL-OMON45821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45821.